» Articles » PMID: 10375549

T Cell Co-stimulatory Molecules Other Than CD28

Overview
Publisher Elsevier
Date 1999 Jun 22
PMID 10375549
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

CD28 is the primary co-stimulatory receptor for inducing high-level IL-2 production and survival of naïve CD4(+) T cells. While no other cell surface receptor can be considered fully redundant with CD28, recent developments suggest that additional co-stimulatory pathways have preferential effects at different stages of T cell activation, on different subsets of T cells or contribute to the development of different effector functions.

Citing Articles

Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer.

Chen Y, Liu S, Yin X Am J Cancer Res. 2025; 15(1):217-232.

PMID: 39949922 PMC: 11815372. DOI: 10.62347/QTWJ8918.


Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.

Li J, Zhou W, Wang W Cell Mol Life Sci. 2024; 81(1):378.

PMID: 39215816 PMC: 11365909. DOI: 10.1007/s00018-024-05412-y.


Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications.

Banerjee A, Aluganti Narasimhulu C, Singla D Am J Physiol Heart Circ Physiol. 2023; 325(4):H751-H767.

PMID: 37594487 PMC: 10659324. DOI: 10.1152/ajpheart.00378.2023.


CAR-T cell potency: from structural elements to vector backbone components.

Mazinani M, Rahbarizadeh F Biomark Res. 2022; 10(1):70.

PMID: 36123710 PMC: 9487061. DOI: 10.1186/s40364-022-00417-w.


Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.

Xu Q, Liu X, Mohseni G, Hao X, Ren Y, Xu Y Cancer Cell Int. 2022; 22(1):242.

PMID: 35906622 PMC: 9338646. DOI: 10.1186/s12935-022-02664-1.